This list is an analysis based on recent market events. It's not an investment recommendation.
About
Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has collaboration agreement with Affilogic, ENA Respiratory Pty Ltd, Lonza, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash University. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.
The current price of ICO.ST is SEK1.18 SEK — it has increased by +2.62% in the past 24 hours. Watch Iconovo AB stock price performance more closely on the chart.
What is Iconovo AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Iconovo AB stocks are traded under the ticker ICO.ST.
What is Iconovo AB market cap?▼
Today Iconovo AB has the market capitalization of 38.79M
When is the next Iconovo AB earnings date?▼
Iconovo AB is going to release the next earnings report on April 24, 2026.
What is Iconovo AB revenue for the last year?▼
Iconovo AB revenue for the last year amounts to 2.81M SEK.
What is Iconovo AB net income for the last year?▼
ICO.ST net income for the last year is -117.12M SEK.
How many employees does Iconovo AB have?▼
As of April 02, 2026, the company has 19 employees.